Video
Dr. Chughtai discusses novel iTind system for BPH treatment
Author(s):
“The data is out to about 2 to 3 years now, so…[it’s] a little bit on the immature side, but it's very promising,” says Bilal Chughtai, MD.
Video Player is loading.
In this video, Bilal Chughtai, MD, assesses the success of the iTind system as reported in the study, “Preservation of ejaculatory and erectile function with iTind system for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia,” presented recently at the 2021 American Urological Association annual meeting. Chughtai is an associate professor of urology, obstetrics and gynecology at Weill Cornell Medicine and an attending urologist at NewYork-Presbyterian Hospital, New York City, New York.
Related Videos
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Endourologist discusses shared decision-making and laser lithotripsy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Related Content
